For the Duration: Dan Browne on Revance's Commitment to Innovation
April 6, 2018
Dan Browne, Steven Dayan, MD
With positive data now available from pivotal phase 3 SAKURA 1 and 2 trials, Revance is eyeing the potential opportunity to bring DaxibotulinumtoxinA for Injection (RT002) to market. Co-Founder, President & Chief Executive Officer Dan Browne talks to Steven Dayan, MD about the data, the pipeline, and the company's long-term focus.